ADC Therapeutics, a leader in antibody drug conjugates, announced it will publish its third-quarter 2026 financial results on November 9, 2026. The company is known for its cancer treatment drug ZYNLONTA, which has FDA accelerated approval and European conditional approval. Investors will be watching for updates on regulatory progress, clinical trials, and revenue forecasts. The results will be available on the company's website in the news section.
ADC Therapeutics' upcoming Q3 2026 financial results are scheduled for November 9, 2026. For readers following the Health sector, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced Health-sector US stocks, 82 rose and 47 fell today. Notable movers include MMED at USD 17.74 with a -2.95% change, MRVI at USD 8.03 with a +2.82% change, and BNGO at USD 1.18 with a +2.61% change. The longest typical hold time among these is 52 Days for BNGO.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
